Skip to main content
Clinical Trials/NCT06730360
NCT06730360RecruitingNot Applicable

Clinical and Radiographic Assessment of Photobiomodulated MTA Pulpotomy in Immature First Permanent Molars with Irreversible Pulpitis: a Randomized Controlled Clinical Trial

Mansoura University1 site in 1 country72 target enrollmentStarted: October 10, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
72
Locations
1
Primary Endpoint
Clinical Success of Pulpotomy Treatment

Study Overview

Brief Summary

This study evaluates the effectiveness of photobiomodulation (PBM) in conjunction with mineral trioxide aggregate (MTA) pulpotomy for treating irreversible pulpitis in immature first permanent molars. PBM, also known as low-level laser therapy (LLLT), is used to enhance healing, reduce inflammation, and manage pain in young teeth. The randomized clinical trial involves 72 children aged 6-9 years, divided into two groups: one receiving MTA pulpotomy alone and the other receiving MTA pulpotomy with PBM. Clinical and radiographic outcomes will be assessed at intervals over 15 months. This research aims to determine the combined therapy's efficacy in improving pulp healing and reducing post-operative discomfort compared to MTA alone.

Detailed Description

This randomized controlled trial evaluates the clinical and radiographic outcomes of MTA pulpotomy, with and without PBM, for immature permanent molars diagnosed with irreversible pulpitis. The study includes two parallel groups of 36 children each. Group I will undergo MTA pulpotomy alone, while Group II will receive PBM treatment alongside MTA pulpotomy.

PBM employs low-level laser therapy to stimulate pulp tissue regeneration, enhance mitochondrial activity, and reduce inflammation and pain, thereby potentially improving MTA pulpotomy outcomes. Key inclusion criteria involve children with deep carious lesions and clinical signs of irreversible pulpitis but without pulpal necrosis. Follow-up will occur at 3, 6, 12, and 15 months post-treatment to evaluate success based on the absence of clinical symptoms (e.g., pain, tenderness) and radiographic indicators of healing.

By comparing these two approaches, the study aims to provide insights into PBM's role as an adjunctive therapy for vital pulp preservation, particularly in pediatric dentistry.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
6 Years to 9 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Children aged 6 to 9 years.
  • •Non-contributory medical history (healthy otherwise).
  • •Presence of carious first permanent molars with the following characteristics:
  • •Deep caries extending to ≥2/3 of dentin.
  • •Positive response to cold testing.
  • •Clinical diagnosis of irreversible pulpitis (moderate or severe), with or without periapical periodontitis.
  • •Restorable tooth.
  • •Probing pocket depth and mobility within normal limits.
  • •No signs of pulpal necrosis, including sinus tract or swelling.

Exclusion Criteria

  • •Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp).
  • •Presence of systemic or medical conditions that may contraindicate participation.
  • •Teeth with unrestorable structure.
  • •Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.

Arms & Interventions

MTA Pulpotomy without Photobiomodulation

Active Comparator

Participants will receive MTA (Mineral Trioxide Aggregate) pulpotomy as a standard treatment without the application of photobiomodulation (low-level laser therapy).

Intervention: MTA Pulpotomy without photobiomodulation (Procedure)

MTA Pulpotomy with Photobiomodulation

Experimental

Participants will receive MTA (Mineral Trioxide Aggregate) pulpotomy treatment enhanced with photobiomodulation (low-level laser therapy). The laser will be applied to pulp stumps before the placement of MTA to promote healing and reduce inflammation.

These entries should resolve the error and align with your protocol.

Intervention: MTA Pulpotomy with Photobiomodulation (LLLT) (Procedure)

Outcomes

Primary Outcomes

Clinical Success of Pulpotomy Treatment

Time Frame: 15 months post-treatment (assessed at 3, 6, 12, and 15 months).

Evaluation of clinical signs and symptoms (absence of pain, tenderness to percussion, sinus tract, or swelling). Treatment is considered successful if these are absent at all follow-up visits.

Secondary Outcomes

  • Radiographic Healing(15 months post-treatment (assessed at 6, 12, and 15 months).)
  • Root Development Progression(15 months post-treatment (assessed at 6, 12, and 15 months))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Peter Samir

assistant lecturer

Mansoura University

Study Sites (1)

Loading locations...

Similar Trials